P844 Frequency of Extraintestinal Manifestations in vedolizumab versus anti-TNF Treated Patients with Inflammatory Bowel Diseases
نویسندگان
چکیده
Abstract Background Patients with moderate to severe inflammatory bowel diseases (IBD) treated gut-selective vedolizumab (VDZ) may be more likely develop de novo extraintestinal manifestations (EIMs) or exacerbate pre-existing EIMs, compared those systemic anti-tumor necrosis factors (anti-TNF), as has been demonstrated mainly in retrospective studies. We aimed compare the frequency of EIMs IBD patients VDZ vs receiving anti-TNF therapies, based on prospectively-retrospectively collected data from a cohort followed daily clinical practice. Methods 300 biopsy-confirmed aged 10–90 years old were included study. A comprehensive questionnaire was used collect each site visit July 2018 until March 2022. Logistic regression analysis and chi-squared test between anti-TNF. Results Of IBD, 111 received biologic therapy [82 Crohn’s disease (CD), 28 ulcerative colitis (UC), 1 indeterminate (IC)]. The median age these 39 years. majority (80%) agents (88 23VDZ). CD frequent (69 88 anti-TNF, OR 2.95; 95% CI: 1.11-7.81; P<.05); UC frequently [10 23 (44%) 18 (21%), P<.05]. diagnosed perianal had an increased trend than without (OR 2.34; 0.87-6.31; P=.094). observed 55% (52% 70% VDZ, P=.144), summarized table 1. 3-fold risk developing exacerbating peripheral arthropathy, 3.03; CI:1.12–8.21; P<.05). Conclusion In this study, agents. This result explained by anti-inflammatory effect which appears limit its EIM prevention.
منابع مشابه
Extraintestinal Manifestations Associated with Inflammatory Bowel Disease.
Inflammatory bowel disease (IBD) affects multiple organ systems outside of the gastrointestinal tract. The clinician treating patients with IBD should be acutely aware of the diagnosis and treatment of extraintestinal manifestations in order to decrease morbidity. The management can be difficult and often times requires a multidisciplinary approach. Future research investigating the pathophysio...
متن کاملAnti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
BACKGROUND Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. METHODS Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS)...
متن کاملExtraintestinal manifestations of inflammatory bowel disease.
Inflammatory bowel disease (IBD) is associated with a variety of extraintestinal manifestations (EIMs) that may produce greater morbidity than the underlying intestinal disease and may even be the initial presenting symptoms of the IBD. As many as 36% of patients with IBD have at least one EIM. Some are more common related to active colitis (joint, skin, ocular, and oral manifestations). Others...
متن کاملExtraintestinal Manifestations of Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) mainly affects the gastrointestinal system but is associated with various chronic diseases of other organs that are jointly called extraintestinal manifestations (EIM). In some of these disorders, onset and clinical manifestations are associated with the course of the intestinal disease while in others they are independent of the intestinal disease. The former i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Crohn's and Colitis
سال: 2023
ISSN: ['1876-4479', '1873-9946']
DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0974